Proscia Introduces Fifth Generation of Concentriq

June 17, 2026 — Proscia has introduced the Fifth Generation of its Concentriq¹ platform, helping pathologists focus on high-judgment decisions and enabling scientists to quickly move from early signals to evidence-based program decisions. Proscia is trusted by diagnostic laboratories that manage 12 million patient cases annually, and 16 of the top 20 pharmaceutical companies.

Pathology sits at the center of how disease is understood and treated. Yet more than half of pathologists report not having enough time to get through their workload², while scientists face mounting pressure to bring targeted therapies to patients, even as most investigational medicines never reach the market. Fifth Generation introduces intelligence that draws on clinical and scientific context to support experts throughout drug discovery, development, and case review.

Making this intelligence native to Concentriq required a new architecture. Designed alongside pathologists and scientists, Fifth Generation is the most significant advancement to Concentriq in five years. It brings domain-specific frontier vision, language and multimodal models to the core of a technology stack built for enterprise-scale security, governance, and reliability.

This architecture enables the platform to unify images, metadata, and the context surrounding a case or study — from slide-level morphology and patient history to laboratory-specific protocols and translational data — giving experts and models the same complete picture. Intelligence draws on this picture to orchestrate the burdensome work surrounding case review and accelerate the discovery and development of advanced biomarkers. Outputs are transparent, reproducible and interpretable for expert verification.

Concentriq Helps Pathologists and Diagnostic Laboratories

Concentriq enables pathologists and laboratories to make a greater impact.

Accelerate case review: Concentriq brings the flow state of the microscope to an enterprise-scale digital platform, combining the microscope’s tactile nature with an understanding of the case and context. Intelligent navigation helps pathologists move quickly through tissue while skin slides orient automatically to preserve the mental model needed to assess findings such as depth of invasion. Context remains connected to the case so that pathologists can move efficiently through tasks like lymph node counts. Image analysis is built directly into the viewer, allowing regions of interest to be refined and results to update in real time with supporting evidence available for expert verification. Reportable findings are assembled in the same pass for pathologist confirmation. The result is greater focus and speed with less manual effort.

Automate laboratory operations: ‍Operations teams keep pace with growing case volumes while maintaining turnaround times. AI helps balance workloads, recommend stain panels and ancillary studies, and surface operational bottlenecks before they impact performance. Purpose-built worklists and dashboards provide visibility across sites and scanners, helping teams keep cases moving without switching tools or chasing down updates. Automated storage tiering matches placement to how each site uses its data, reducing long-term storage costs by more than half³ while preserving secure, governed access to the cases that power re-review, future AI validation, and biopharmaceutical collaborations.

Drive business growth: Laboratories can expand into high-margin specialty testing and grow their role in precision medicine. Molecular workflows inside Concentriq reduce manual handoffs and optimize tissue at every step with digital macro dissection and native AI tumor detection, making advanced molecular testing easier to scale with high-quality data. Through the network Concentriq enables, laboratories can collaborate with biopharmaceutical companies on real-world data programs, clinical trials, and companion diagnostic development, among other initiatives.

The fifth generation of Concentriq is available now to current customers through Proscia's early access program. Initial deployments begin this month with select laboratories and biopharmaceutical companies, and broader availability follows later this year. Organizations not yet on Concentriq can request priority access by contacting Proscia.

1. The Concentriq portfolio includes distinct configurations. Concentriq AP-Dx is FDA-cleared for primary diagnosis in the United States (U.S.) with the Hamamatsu NanoZoomer® S360MD Slide scanner and is licensed in Canada and CE‑marked under the EU IVDR for primary diagnosis.Concentriq AP-Dx is not intended for use with frozen sections, cytology, ornon-FFPE hematopathology specimens. Concentriq AP and Concentriq LS are for Research Use Only. Not for use in diagnostic procedures. Proscia’s AI applications are available for research use only. Many of the features described herein are part of Concentriq AP and are not for use in clinical diagnosis.

2. RoyalCollege of Pathologists. Workforce census 2025: morale and wellbeing of the pathology workforce. Royal College of Pathologists; August 11, 2025. AccessedMarch 23, 2026.  www.rcpath.org/discover-pathology/news/workforce-census-2025-morale-and-wellbeing-of-the-pathology-workforce.html

3. Automatic tiering with cold storage cuts long-term costs by more than half for labs already using tiered storage. Based on modeling with real lab usage data, including retrieval rates. Actual savings may vary by policy or deployment.